Week 12 | Vobarilizumab | Vobarilizumab | Vobarilizumab (N=63) | Tocilizumab |
---|---|---|---|---|
(% of patients) | 150mg q4w | 150mg q2w | 225mg q2w | 162mg q1w (N=60) |
(N=62) | (N=62) | (N=63) | q2w (N=4) | |
ACR20 | 73 | 77 | 81 | 78 |
ACR50 | 44 | 37 | 49 | 45 |
ACR70 | 16 | 24 | 21 | 23 |
HAQ-DI score decrease ≥0.25 | 65 | 68 | 71 | 72 |
DAS28ESR<2.6 | 34 | 21 | 40 | 25 |
DAS28CRP<2.6 | 26 | 27 | 41 | 27 |
SDAI remission | 8 | 5 | 8 | 11 |
CDAI remission | 10 | 5 | 6 | 9 |